SEP 16, 2015
AngioPlex OCT angiography, which can image the retina without the use of fluorescence, has received clearance from the U.S. FDA.
Using the Cirrus HD-OCT system, AngioPlex requires a single additional scan that takes just seconds to provide high-resolution, depth-resolved visualization of the layers of the retinal and choroidal vasculature without an injected contrast dye, according to ZEISS Medical Technology.
“Retinal specialists will now be able to obtain high-resolution cross-sectional images of the macula coupled to the most detailed visualization of the retinal vasculature ever achieved,” Carmen A. Puliafito, MD, MBA, said in a press release. “This unique capability promises to revolutionize clinical decision making in retinal pharmacotherapy.”
To assess treatment efficacy and monitor disease progression, AngioPlex uses FastTrac to eliminate eye motion and enable follow-up OCT angiography images to be acquired at the same location. The system is powered by optical microangiography algorithms, an image processing technique used to provide high-quality OCT angiography images.
CE mark for AngioPlex in the European Union is pending.